some commentaries from Milford:
Performance was led by Neuren Pharmaceuticals which rallied 61.1% following the successful readout results for its NNZ-2591 drug which treats the debilitating Phelan McDermid Syndrome. The consistency of the results, efficacy and benign safety profile exceeded our high expectations. The company remains catalyst rich, with Daybue quarterly sales update due in February, and additional topline results for its drug in Pitt-Hopkins, Prader-Willi and Angelman syndromes over the next 12 months
Judging by their latest top company holding list, they appeared to have added NEU to their position in Dec following the results as it has reappeared in their top 5 list
Neuren Media and Analyst Coverage, page-729
-
- There are more pages in this discussion • 598 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.070(0.45%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.80 | $15.37 | $6.881M | 441.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35 | $15.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.64 | 2103 | 1 |
View Market Depth
| Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |